2A Biosciences Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$3.78M
- Investors
-
13
2A Biosciences General Information
Description
Developer of proprietary small-molecule drug candidates designed for regenerative and anti-inflammatory therapeutic outcomes. The company's platform uses precise molecular designs to develop non-hallucinogenic compounds that selectively activate the Serotonin 2A receptor, modulating biological processes related to neuroregeneration, mitochondrial biogenesis, and inflammation resolution, enabling individuals suffering from a range of degenerative and chronic inflammatory diseases, such as neurodegenerative eye conditions, to access novel, disease-modifying treatment options.
Contact Information
Website
www.2abiosci.comCorporate Office
- 1714 Bryn Mawr
- Santa Monica, CA 90405
- United States
Corporate Office
- 1714 Bryn Mawr
- Santa Monica, CA 90405
- United States
2A Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Seed Round | 26-Jul-2023 | $3.78M | Completed | Clinical Trials - Phase 1 | ||
| 1. Seed Round | 01-Jan-2022 | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
2A Biosciences Patents
2A Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026198728-A1 | 1,3-dihydro-4-isobenzofuranethanamines | Pending | 18-Mar-2025 | ||
| WO-2025240982-A1 | 5-alkoxymethyl and 5-hydroxymethyl phenethylamines | Pending | 17-May-2024 | ||
| US-12692221-B2 | 5-methoxymethyl and 5-hydroxymethyl phenethylamines | Active | 17-May-2024 | ||
| US-20250353808-A1 | 5-methoxymethyl and 5-hydroxymethyl phenethylamines | Active | 17-May-2024 | ||
| WO-2025217471-A1 | 2-hemifly phenethylamines | Pending | 10-Apr-2024 | A61P25/28 |
2A Biosciences Signals
2A Biosciences Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Boost VC | Accelerator/Incubator | Minority | ||
| Calm Ventures | Venture Capital | Minority | ||
| Capital Factory | Accelerator/Incubator | Minority | ||
| DecentraNet | Venture Capital | Minority | ||
| Gaingels | Venture Capital | Minority |
2A Biosciences FAQs
-
When was 2A Biosciences founded?
2A Biosciences was founded in 2022.
-
Where is 2A Biosciences headquartered?
2A Biosciences is headquartered in Santa Monica, CA.
-
What is the size of 2A Biosciences?
2A Biosciences has 10 total employees.
-
What industry is 2A Biosciences in?
2A Biosciences’s primary industry is Drug Discovery.
-
Is 2A Biosciences a private or public company?
2A Biosciences is a Private company.
-
What is 2A Biosciences’s current revenue?
The current revenue for 2A Biosciences is .
-
How much funding has 2A Biosciences raised over time?
2A Biosciences has raised $3.78M.
-
Who are 2A Biosciences’s investors?
Boost VC, Calm Ventures, Capital Factory, DecentraNet, and Gaingels are 5 of 13 investors who have invested in 2A Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process